He received his DPhil in Pharmacology from the University of Oxford with Professor Edith Sim. In his graduate work he identified and characterized a carbon-carbon hydrolase involved in mycobacterial cholesterol metabolism. Following this, he went on to conduct a Postdoctoral fellowship from 2009-2011 at the Vancouver Prostate Center in the University of British Columbia. In addition, he also worked for the pharmaceutical company AnorMED and was involved in the development of the FDA approved therapeutic Plerixafor. His current research is focused on the development of novel functional genomic techniques to characterize androgen receptor signaling. Sabancı University